Prosensa receives £7.5m milestone payment as part of its program with GlaxoSmithKline in Duchenne Muscular Dystrophy

15-Oct-2010 - Netherlands

Prosensa has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne muscular dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed. GSK2402968 (PRO051) is an investigational antisense oligonucleotide which induces exon skipping of exon 51.

Under their collaboration, Prosensa and GSK have several further late-stage clinical trials underway.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?